Loading...
XSHE002550
Market cap1.01bUSD
Jan 14, Last price  
5.90CNY
1D
1.90%
1Q
-3.59%
Jan 2017
-18.28%
IPO
15.69%
Name

Changzhou Qianhong Biopharma Co Ltd

Chart & Performance

D1W1MN
XSHE:002550 chart
P/E
40.55
P/S
4.06
EPS
0.15
Div Yield, %
2.07%
Shrs. gr., 5y
-0.05%
Rev. gr., 5y
6.54%
Revenues
1.81b
-21.24%
285,596,136471,642,506743,796,7731,144,767,230737,652,806728,592,036860,780,976814,608,253757,051,128776,388,9721,065,466,1011,321,678,6231,675,153,0961,667,606,5971,874,936,5272,303,547,7901,814,268,908
Net income
182m
-43.77%
45,625,39090,438,283125,693,491150,527,650152,248,050161,802,960187,021,741245,036,732267,151,247224,461,503183,004,861221,349,044262,561,1710181,079,595323,414,382181,860,747
CFO
533m
35,993,92354,358,6398,350,418171,514,855146,820,474199,823,986160,472,338252,012,794286,504,054221,014,95288,518,99525,445,967161,547,891317,277,947103,560,5040533,327,999
Dividend
May 29, 20240.12 CNY/sh
Earnings
May 16, 2025

Profile

Changzhou Qianhong Biopharma CO.,LTD engages in the research and development, production, and sale of bio-pharmaceutical products with a focus on polysaccharides and enzymes in China. The company provides various API products, including heparin sodium, heparin calcium, enoxaparin sodium, nadroparin calcium, and dalteparin sodium for use as anticoagulants; pancreatin for use as a digestive agent; asparaginase for use as an antineoplastic agent; kallidinogenase kallikrein for use in the treatment of microcirculation disorders; and heparinoid. It also offers a range of preparations, such as nadroparin calcium PFS, enoxaparin sodium PFS, dalteparin sodium PFS, and asparaginase and heparin sodium injections for use as anticoagulants. In addition, the company exports its products. Changzhou Qianhong Biopharma CO.,LTD was founded in 1971 and is headquartered in Changzhou, China.
URL
https://www.qhsh.com.cn/
IPO date
Feb 18, 2011
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,814,269
-21.24%
2,303,548
22.86%
Cost of revenue
1,491,125
1,964,689
Unusual Expense (Income)
NOPBT
323,144
338,859
NOPBT Margin
17.81%
14.71%
Operating Taxes
24,851
40,420
Tax Rate
7.69%
11.93%
NOPAT
298,292
298,439
Net income
181,861
-43.77%
323,414
78.60%
Dividends
(152,976)
(149,976)
Dividend yield
2.00%
1.87%
Proceeds from repurchase of equity
(30,094)
BB yield
0.39%
Debt
Debt current
55,623
100,095
Long-term debt
Deferred revenue
89,353
Other long-term liabilities
81,846
1
Net debt
(860,754)
(465,943)
Cash flow
Cash from operating activities
533,328
CAPEX
(100,332)
Cash from investing activities
Cash from financing activities
(190,873)
11,017
FCF
622,564
(61,591)
Balance
Cash
713,157
476,733
Long term investments
203,220
89,306
Excess cash
825,663
450,861
Stockholders' equity
2,483,399
2,433,179
Invested Capital
1,785,713
2,169,199
ROIC
15.08%
15.42%
ROCE
12.35%
12.91%
EV
Common stock shares outstanding
1,299,005
1,279,800
Price
5.88
-6.07%
6.26
29.61%
Market cap
7,638,151
-4.66%
8,011,548
32.72%
EV
6,796,375
7,545,605
EBITDA
392,362
403,622
EV/EBITDA
17.32
18.69
Interest
6,168
5,234
Interest/NOPBT
1.91%
1.54%